Gilead Sciences, Inc GILD:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
After Hours: Last | 5:16 PM EDT130.00
+1.01 (+0.78%)
+1.01 (+0.78%)Volume
272,465
Close
128.99+1.42 (+1.11%)
+1.42 (+1.11%)Volume
5,908,230
52 week range
104.46 - 157.29
- Open127.59
- Day High129.86
- Day Low127.50
- Prev Close127.57
- 52 Week High157.29
- 52 Week High Date02/11/26
- 52 Week Low104.46
- 52 Week Low Date06/25/25
Latest On Gilead Sciences, Inc
Key Stats
- Market Cap160.15B
- Shares Out1.24B
- 10 Day Average Volume7.04M
- Dividend3.28
- Dividend Yield2.54%
- Beta0.33
Latest On Gilead Sciences, Inc
KEY STATS
- Open127.59
- Day High129.86
- Day Low127.50
- Prev Close127.57
- 52 Week High157.29
- 52 Week High Date02/11/26
- 52 Week Low104.46
- 52 Week Low Date06/25/25
- Market Cap160.15B
- Shares Out1.24B
- 10 Day Average Volume7.04M
- Dividend3.28
- Dividend Yield2.54%
- Beta0.33
RATIOS/PROFITABILITY
- EPS (TTM)7.35
- P/E (TTM)17.55
- Fwd P/E (NTM)-160.44
- EBITDA (TTM)14.693B
- ROE (TTM)43.19%
- Revenue (TTM)29.736B
- Gross Margin (TTM)79.37%
- Net Margin (TTM)31.00%
- Debt To Equity (MRQ)94.30%
EVENTS
- Earnings Date08/05/2026(est)
- Ex Div Date06/15/2026
- Div Amount0.82
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREGilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP...
Daniel O'Day
Chairman of the Board, Chief Executive Officer
Andrew Dickinson
Chief Financial Officer
Keeley Cain Wettan
Executive Vice President, General Counsel, Legal and Compliance
Address
333 LAKESIDE DR
Foster City, CA
94404-1147
United States